NASDAQ:AURA Aura Biosciences (AURA) Stock Price, News & Analysis → The Long-Awaited End of America Update (From Stansberry Research) (Ad) Free AURA Stock Alerts $7.59 -0.06 (-0.78%) (As of 11:00 AM ET) Add Compare Share Share Today's Range$7.46▼$7.7650-Day Range$7.03▼$9.2452-Week Range$5.99▼$13.50Volume14,593 shsAverage Volume163,971 shsMarket Capitalization$375.93 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Aura Biosciences alerts: Email Address Aura Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside174.5% Upside$21.00 Price TargetShort InterestBearish6.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.02) to ($1.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.90 out of 5 starsMedical Sector821st out of 924 stocksBiological Products, Except Diagnostic Industry138th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingAura Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAura Biosciences has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.50% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 14.2, which indicates bearish sentiment.Change versus previous monthShort interest in Aura Biosciences has recently increased by 5.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAura Biosciences does not currently pay a dividend.Dividend GrowthAura Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AURA. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Aura Biosciences this week, compared to 1 article on an average week.Search Interest6 people have searched for AURA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aura Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Aura Biosciences is held by insiders.Percentage Held by Institutions96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aura Biosciences are expected to grow in the coming year, from ($2.02) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aura Biosciences is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aura Biosciences is -3.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAura Biosciences has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. About Aura Biosciences Stock (NASDAQ:AURA)Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Read More AURA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AURA Stock News HeadlinesMay 2, 2024 | americanbankingnews.comReviewing Aura Biosciences (NASDAQ:AURA) & Elevation Oncology (NASDAQ:ELEV)April 20, 2024 | msn.comFF16 Ultima Abilities And How To Unlock Them In The Rising TideMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.March 29, 2024 | msn.com3 Best Stocks to Buy Now, 3/29/2024, According to Top AnalystsMarch 29, 2024 | markets.businessinsider.comAura Biosciences Inc: A Buy Rating on Strong Pipeline and Financial HealthMarch 28, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF), Molina Healthcare (MOH) and Aura Biosciences Inc (AURA)March 28, 2024 | finance.yahoo.comWe're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn RateMarch 27, 2024 | investorplace.comAURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023May 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.March 27, 2024 | benzinga.comRecap: Aura Biosciences Q4 EarningsMarch 27, 2024 | businesswire.comAura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsMarch 13, 2024 | msn.comNational Assembly Counters Doctors Petition on SHIFFebruary 26, 2024 | businesswire.comAura Biosciences to Participate in Upcoming Investor ConferencesFebruary 23, 2024 | benzinga.comAura Biosciences Stock (NASDAQ:AURA), Short Interest ReportJanuary 7, 2024 | finance.yahoo.comOwning 48% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA),January 3, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Aura Biosciences Inc (AURA)December 11, 2023 | finance.yahoo.comWall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a BetDecember 9, 2023 | benzinga.comAura Biosciences Stock (NASDAQ:AURA), Analyst Ratings, Price Targets, PredictionsDecember 7, 2023 | finance.yahoo.comAura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal MelanomaNovember 23, 2023 | finance.yahoo.comWall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to TradeNovember 13, 2023 | markets.businessinsider.comCorrection: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common StockNovember 12, 2023 | finance.yahoo.comDavid Johnson Bought 232% More Shares In Aura BiosciencesNovember 11, 2023 | msn.comInsider Trading: Aura Biosciences Stock (NASDAQ:AURA) Bought by Insiders to the Tune of $16MNovember 10, 2023 | msn.comAura Biosciences director David Johnson buys common shares worth ~$1.44MNovember 10, 2023 | markets.businessinsider.comPortfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common StockNovember 8, 2023 | markets.businessinsider.comPromising Phase 2 Trial Results and Market Potential Bolster Aura Biosciences’ Buy RatingNovember 7, 2023 | msn.comWhy Aura Biosciences Stock Hit A New 52-Week Low TodaySee More Headlines Receive AURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today5/01/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:AURA CUSIPN/A CIK1501796 Webwww.aurabiosciences.com Phone617-500-8864FaxN/AEmployees88Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$23.00 Low Stock Price Target$19.00 Potential Upside/Downside+174.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.20% Return on Assets-36.66% Debt Debt-to-Equity RatioN/A Current Ratio18.76 Quick Ratio18.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.58 per share Price / Book1.67Miscellaneous Outstanding Shares49,530,000Free Float46,611,000Market Cap$378.90 million OptionableNot Optionable Beta0.36 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Elisabet de los Pinos Ph.D. (Age 51)Founder, CEO, President & Director Comp: $795.3kMs. Julie B. Feder (Age 54)CFO, Secretary & Treasurer Comp: $505.45kMr. Patrick NealonSenior Vice President of Clinical Development OperationsDr. Bruce Brown M.D.Senior VP & Therapeutic Area Head of Urologic OncologyDr. Anthony Daniels M.D.Therapeutic Area Head of Ocular OncologyDr. Richard Mountfield Ph.D.Senior Vice President of Regulatory Affairs & QualityMore ExecutivesKey CompetitorsTScan TherapeuticsNASDAQ:TCRXJasper TherapeuticsNASDAQ:JSPRTenaya TherapeuticsNASDAQ:TNYAAdaptive BiotechnologiesNASDAQ:ADPTiTeos TherapeuticsNASDAQ:ITOSView All CompetitorsInsiders & InstitutionsEventide Asset Management LLCBought 2,777,777 shares on 2/20/2024Ownership: 15.166%Platinum Investment Management Ltd.Bought 180,145 shares on 2/14/2024Ownership: 0.471%Matrix Capital Management Company LPBought 1,560,000 shares on 2/13/2024Ownership: 18.094%Tower Research Capital LLC TRC Sold 2,307 shares on 2/13/2024Ownership: 0.011%Monashee Investment Management LLCBought 198,415 shares on 2/12/2024Ownership: 0.519%View All Insider TransactionsView All Institutional Transactions AURA Stock Analysis - Frequently Asked Questions Should I buy or sell Aura Biosciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AURA shares. View AURA analyst ratings or view top-rated stocks. What is Aura Biosciences' stock price target for 2024? 3 equities research analysts have issued 1 year price targets for Aura Biosciences' stock. Their AURA share price targets range from $19.00 to $23.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 174.5% from the stock's current price. View analysts price targets for AURA or view top-rated stocks among Wall Street analysts. How have AURA shares performed in 2024? Aura Biosciences' stock was trading at $8.86 at the beginning of the year. Since then, AURA shares have decreased by 13.7% and is now trading at $7.65. View the best growth stocks for 2024 here. Are investors shorting Aura Biosciences? Aura Biosciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,450,000 shares, an increase of 9.4% from the March 15th total of 2,240,000 shares. Based on an average daily trading volume, of 179,700 shares, the short-interest ratio is presently 13.6 days. Currently, 6.2% of the company's shares are sold short. View Aura Biosciences' Short Interest. When is Aura Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our AURA earnings forecast. How were Aura Biosciences' earnings last quarter? Aura Biosciences, Inc. (NASDAQ:AURA) issued its quarterly earnings data on Wednesday, March, 27th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.11. What ETFs hold Aura Biosciences' stock? ETFs with the largest weight of Aura Biosciences (NASDAQ:AURA) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Loncar China Biopharma ETF (CHNA).AltShares Event-Driven ET (EVNT). When did Aura Biosciences IPO? Aura Biosciences (AURA) raised $81 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 5,400,000 shares at a price of $14.00-$16.00 per share. Who are Aura Biosciences' major shareholders? Aura Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Cadmus Rich, David Michael Johnson, Julie B Feder, Los Pinos Elisabet De, Matrix Capital Management Comp and Rosch Mark De. View institutional ownership trends. How do I buy shares of Aura Biosciences? Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AURA) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsA once-in-a-century investment opportunityStansberry ResearchPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
